/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

M

Michal Juraska

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa(ZA)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

91

Papers

2.8K

Citations

23

h-index

36

i10-index

Michal Juraska is an academic researcher from Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa. The author has contributed to research in topics: HIV Research and Treatment & HIV/AIDS drug development and treatment & HIV/AIDS Research and Interventions. The author has an h-index of 23, co-authored 78 publications.

ORCID: 0000-0002-0920-2915

Research Topics

HIV Research and Treatment HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions SARS-CoV-2 and COVID-19 Research Monoclonal and Polyclonal Antibodies Research

Papers by this author

works

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

2022 · Nature Medicine · 112 citations

https://doi.org/10.1038/s41591-022-01953-6

Peter B. Gilbert Yunda Huang Allan C. deCamp Shelly Karuna

A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings

2021 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 45 citations

https://doi.org/10.1097/qai.0000000000002649

Nyaradzo Mgodi Simbarashe Takuva Srilatha Edupuganti Shelly Karuna

HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy

2019 · BMC Infectious Diseases · 40 citations

https://doi.org/10.1186/s12879-019-4049-5

Peter B. Gilbert Youyi Fong Michal Juraska Lindsay N. Carpp

Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial

2024 · The Lancet Infectious Diseases · 29 citations

https://doi.org/10.1016/s1473-3099(24)00358-x

Glenda Gray Kathryn Mngadi Ludo Lavreys Steven Nijs

High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials

2023 · Nature Communications · 18 citations

https://doi.org/10.1038/s41467-023-43384-y

Daniel B. Reeves Bryan T. Mayer Allan C. deCamp Yunda Huang

Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study

2024 · EBioMedicine · 13 citations

https://doi.org/10.1016/j.ebiom.2024.105320

Avi Kenny Janine van Duijn One Dintwe Jack Heptinstall

Research topics

topics

HIV Research and Treatment

HIV/AIDS drug development and treatment

HIV/AIDS Research and Interventions

SARS-CoV-2 and COVID-19 Research

Monoclonal and Polyclonal Antibodies Research

Chat about Author

Papers

Chat

Click to start Chat